Evidence map›Paper›PMID 29800117›Full record

ArticleJAMA dermatology2018

Potential Association of Anti-CCR4 Antibody Mogamulizumab and Graft-vs-Host Disease in Patients With Mycosis Fungoides and Sézary Syndrome.

Julia Dai, Timothy H Almazan, Eric K Hong, Michael S Khodadoust, Sally Arai, Wen-Kai Weng, Youn H Kim

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in JAMA dermatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Clinical and Real-World Effectiveness of Mogamulizumab: A Narrative Review.International journal of molecular sciences · 2024
    Review
  6. Review
  7. Cutaneous Lymphoma and Antibody-Directed Therapies.Antibodies (Basel, Switzerland) · 2023
    Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Julia DaiDepartment of Dermatology, Stanford University, Stanford, California.
Timothy H AlmazanDepartment of Dermatology, Stanford University, Stanford, California.
Eric K HongDepartment of Dermatology, Stanford University, Stanford, California.
Michael S KhodadoustDivision of Oncology, Department of Medicine, Stanford University, Stanford, California.
Sally AraiDivision of Blood and Marrow Transplantation, Department of Medicine, Stanford University, Stanford, California.
Wen-Kai WengDepartment of Dermatology, Stanford University, Stanford, California.
Youn H KimDepartment of Dermatology, Stanford University, Stanford, California.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AgedAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalFemaleGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHumansMaleMiddle AgedMycosis FungoidesProgression-Free SurvivalRetrospective StudiesSezary SyndromeSkin NeoplasmsSurvival RateTransplantation, HomologousAntibodies, Monoclonal, HumanizedAntineoplastic Agents, Immunologicalmogamulizumab

Identifiers

PMID29800117
PMCPMC6145646

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.